Riyue Bao

Apr 24, 2024 | nature.com | Meenakshi Hegde |Shoba Navai |Khaled Sanber |Ahmed Gad |Riyue Bao |Ahmed Salem | +5 more

AbstractIn this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu) ± cyclophosphamide (Cy): 1 × 108 T cells per m2 after Flu (cohort A) or Flu/Cy (cohort B) and 1 × 108 CAR+ T cells per m2 after Flu/Cy (cohort C). The primary outcome was assessment of safety of one dose of HER2 CAR T cells after lymphodepletion.